The University of Chicago Header Logo

Connection

Sushila R. Dalal to Female

This is a "connection" page, showing publications Sushila R. Dalal has written about Female.
Connection Strength

0.183
  1. Ustekinumab Is Effective for the Treatment of Chronic Antibiotic-Refractory Pouchitis. Dig Dis Sci. 2019 12; 64(12):3596-3601.
    View in: PubMed
    Score: 0.034
  2. Early Transcriptomic Changes in the Ileal Pouch Provide Insight into the Molecular Pathogenesis of Pouchitis and Ulcerative Colitis. Inflamm Bowel Dis. 2017 03; 23(3):366-378.
    View in: PubMed
    Score: 0.029
  3. Real World Clinical Effectiveness and Safety of Ozanimod in the Treatment of Ulcerative Colitis: 1-Year Follow-Up from a Tertiary Center. Dig Dis Sci. 2024 Feb; 69(2):579-587.
    View in: PubMed
    Score: 0.012
  4. Inpatient Therapy With Calcineurin Inhibitors in Severe Ulcerative Colitis. Inflamm Bowel Dis. 2021 10 18; 27(10):1620-1625.
    View in: PubMed
    Score: 0.010
  5. Effective Treatment of Acute Severe Ulcerative Colitis in Pregnancy Is Associated With Good Maternal and Fetal Outcomes. Clin Gastroenterol Hepatol. 2021 11; 19(11):2444-2446.e2.
    View in: PubMed
    Score: 0.009
  6. Risk factors and treatment outcomes of peristomal pyoderma gangrenosum in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2020 06; 51(12):1365-1372.
    View in: PubMed
    Score: 0.009
  7. Efficacy and safety of induction therapy with calcineurin inhibitors followed by vedolizumab maintenance in 71 patients with severe steroid-refractory ulcerative colitis. Aliment Pharmacol Ther. 2020 03; 51(6):637-643.
    View in: PubMed
    Score: 0.009
  8. Outcome of elective switching to vedolizumab in inflammatory bowel disease patients under tumor necrosis factor antagonist-maintained clinical remission. J Gastroenterol Hepatol. 2019 Dec; 34(12):2090-2095.
    View in: PubMed
    Score: 0.009
  9. Real-World Experience with Tofacitinib in IBD at a Tertiary Center. Dig Dis Sci. 2019 07; 64(7):1945-1951.
    View in: PubMed
    Score: 0.008
  10. Differential risk of disease progression between isolated anastomotic ulcers and mild ileal recurrence after ileocolonic resection in patients with Crohn's disease. Gastrointest Endosc. 2019 08; 90(2):269-275.
    View in: PubMed
    Score: 0.008
  11. A comparison of the risk of postoperative recurrence between African-American and Caucasian patients with Crohn's disease. Aliment Pharmacol Ther. 2018 11; 48(9):933-940.
    View in: PubMed
    Score: 0.008
  12. Clinical Response and Complications are not Associated with Drug Levels in Patients with Severe Ulcerative Colitis on IV Cyclosporine Induction Therapy. Inflamm Bowel Dis. 2018 05 18; 24(6):1291-1297.
    View in: PubMed
    Score: 0.008
  13. The Use of Vedolizumab in Preventing Postoperative Recurrence of Crohn's Disease. Inflamm Bowel Dis. 2018 02 15; 24(3):502-509.
    View in: PubMed
    Score: 0.008
  14. Risk Factors for Clostridium difficile Isolation in Inflammatory Bowel Disease: A Prospective Study. Dig Dis Sci. 2018 04; 63(4):1016-1024.
    View in: PubMed
    Score: 0.008
  15. Risk of Postoperative Complications Among Inflammatory Bowel Disease Patients Treated Preoperatively With Vedolizumab. Am J Gastroenterol. 2017 Sep; 112(9):1423-1429.
    View in: PubMed
    Score: 0.007
  16. Insights into the pathogenesis of ulcerative colitis from a murine model of stasis-induced dysbiosis, colonic metaplasia, and genetic susceptibility. Am J Physiol Gastrointest Liver Physiol. 2016 06 01; 310(11):G973-88.
    View in: PubMed
    Score: 0.007
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.